Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Last trade$28.95
Day change-$0.22 (-0.75%)
Day range$28.47 – $29.39
Volume203,250
Market cap$1.24B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.24B
Price / earnings
12.57×
Price / book
1.53×
Price / sales
1.67×
EV / sales
2.22×
EV / EBITDA
8.33×
Profitability
Earnings per share
$2.32
Return on assets
5.78%
Return on equity
12.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.75×
Current ratio
3.32×
Quick ratio
2.36×
Cash ratio
1.13×
Cash flow
Price / cash flow
7.1×
Price / free cash flow
8.95×
Free cash flow
$139.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AMPH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$207.61M
$183.9M
$171.17M
$183.11M
$191.84M
$174.41M
$170.53M
$186.52M
Cost of revenue
$107.98M
$90.43M
$100.85M
$97.44M
$93.19M
$87.92M
$85.28M
$99.88M
Gross profit
$99.63M
$93.47M
$70.32M
$85.67M
$98.65M
$86.49M
$85.25M
$86.65M
Selling, general and administrative
$28.78M
$31.58M
$29.96M
$26.75M
$50.97M
$24.23M
$27.86M
$23.36M
Research and development
$20.08M
$22.16M
$26.74M
$23.31M
$22.35M
$20.08M
$20.1M
$18.14M
Total operating expenses
$48.86M
$53.74M
$56.69M
$50.06M
$73.33M
$44.31M
$47.96M
$41.5M
Operating income
$50.77M
$39.73M
$13.63M
$35.61M
$25.32M
$42.18M
$37.29M
$45.14M
Interest expense
-$6.76M
-$6.66M
-$6.55M
-$6.63M
-$6.28M
-$6.28M
-$6.29M
-$6.43M
Income before taxes
$49.06M
$38.54M
$10.05M
$31.91M
$21.51M
$39.34M
$30.86M
$43.96M
Income taxes
$11.3M
$8.2M
$3.63M
$7.49M
$4.16M
$8.31M
$5.58M
$6M
Net income
$37.76M
$30.35M
$6.42M
$24.43M
$17.35M
$31.03M
$25.29M
$37.96M
Net income attributable to common shareholders
$37.76M
$30.35M
$6.42M
$24.43M
$17.35M
$31.03M
$25.29M
$37.96M
EBITDA
$66.36M
$54.04M
$27.98M
$49.95M
$39.45M
$56.8M
$50.9M
$58.58M
Basic earnings per share
$0.89
$0.69
$0.14
$0.53
$0.38
$0.66
$0.53
$0.89
Diluted earnings per share
$0.87
$0.67
$0.14
$0.52
$0.37
$0.64
$0.51
$0.83
Recent news
Company coverage with links to the original publishers.
Amphastar Pharmaceuticals reported Q3 2026 revenue of $207.61 million, up 8.2% year-over-year and beating consensus estimates by 6.72%. EPS of $1.14 significantly exceeded the $0.78 estimate by 46.15%. Key product performance was mixed: Primatene MIST and BAQSIMI exceeded expectations with strong growth, while Epinephrine and Glucagon declined significantly. Lidocaine showed robust growth. Despite strong earnings beats, the stock carries a Zacks Rank #4 (Sell) rating.
Bausch Health reported quarterly earnings of $1.77 per share, significantly beating the consensus estimate of $1.08 and surpassing revenue expectations. The company received a Zacks Rank #2 (Buy) rating despite underperforming the S&P 500 by 22% year-to-date. Amphastar Pharmaceuticals is expected to report lower earnings with a -16.1% year-over-year decline.
Zacks highlights Amphastar Pharmaceuticals (AMPH) as an attractive value stock with a Zacks Rank #2 (Buy) rating and an 'A' grade for Value. The stock trades at a P/E ratio of 7.81 compared to its industry average of 15.87, along with favorable P/B and P/S ratios, suggesting it is currently undervalued by the market.
The generic drug industry shows mixed but resilient performance with companies focusing on operational efficiency and portfolio optimization. Three standout stocks—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through new product launches, biosimilar expansion, and complex generics development. However, the industry faces persistent pricing pressure and competition, with the Zacks Medical-Generic Drugs industry ranked #160 out of 247 industries.
The generic drug industry is experiencing a mixed but resilient operating environment with pricing pressures offset by healthy underlying demand and new product launches. Three companies—Amphastar Pharmaceuticals, Sandoz, and Viatris—are well-positioned to capitalize on industry evolution through biosimilar expansion, complex generics development, and operational efficiency improvements. The industry currently trades at a valuation discount compared to broader market indices.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.